Tags

Type your tag names separated by a space and hit enter

Cost and comorbidities associated with opioid abuse in managed care and Medicaid patients in the United Stated: a comparison of two recently published studies.
J Pain Palliat Care Pharmacother. 2010 Sep; 24(3):251-8.JP

Abstract

Opioid abuse places a large burden on the U.S. society. Two similarly designed studies recently identified the economic and health impact of opioid abuse in patients with private or Medicaid insurance. The prevalence of opioid abuse was estimated to be over 10 times higher in Medicaid beneficiaries than private insurance populations, 87 versus 8 per 10,000, respectively. Opioid abusers incurred annual medical costs that were $14,054 to $6650 higher than nonabusers in patients with private insurance or Medicaid beneficiaries, respectively (P < .01 for both). Annual costs were similar for abusers with private insurance ($15,884) or Medicaid beneficiaries ($13,658). Costs for nonabuser Medicaid beneficiaries were $7008 versus $1830 for those with private insurance, which likely reflects the lower health status of the overall Medicaid population. In both studies, the prevalence of comorbidities associated with substance abuse or chronic pain were significantly higher in abusers than nonabusers. These studies confirm that opioid abuse is associated with comorbidities that increase direct medical costs for patients with private insurance and for Medicaid beneficiaries, increasing the societal burden of opioid abuse.

Authors+Show Affiliations

Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, Utah 84108, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

20718646

Citation

Ghate, Sameer R., et al. "Cost and Comorbidities Associated With Opioid Abuse in Managed Care and Medicaid Patients in the United Stated: a Comparison of Two Recently Published Studies." Journal of Pain & Palliative Care Pharmacotherapy, vol. 24, no. 3, 2010, pp. 251-8.
Ghate SR, Haroutiunian S, Winslow R, et al. Cost and comorbidities associated with opioid abuse in managed care and Medicaid patients in the United Stated: a comparison of two recently published studies. J Pain Palliat Care Pharmacother. 2010;24(3):251-8.
Ghate, S. R., Haroutiunian, S., Winslow, R., & McAdam-Marx, C. (2010). Cost and comorbidities associated with opioid abuse in managed care and Medicaid patients in the United Stated: a comparison of two recently published studies. Journal of Pain & Palliative Care Pharmacotherapy, 24(3), 251-8. https://doi.org/10.3109/15360288.2010.501851
Ghate SR, et al. Cost and Comorbidities Associated With Opioid Abuse in Managed Care and Medicaid Patients in the United Stated: a Comparison of Two Recently Published Studies. J Pain Palliat Care Pharmacother. 2010;24(3):251-8. PubMed PMID: 20718646.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost and comorbidities associated with opioid abuse in managed care and Medicaid patients in the United Stated: a comparison of two recently published studies. AU - Ghate,Sameer R, AU - Haroutiunian,Simon, AU - Winslow,Roger, AU - McAdam-Marx,Carrie, PY - 2010/8/20/entrez PY - 2010/8/20/pubmed PY - 2010/12/14/medline SP - 251 EP - 8 JF - Journal of pain & palliative care pharmacotherapy JO - J Pain Palliat Care Pharmacother VL - 24 IS - 3 N2 - Opioid abuse places a large burden on the U.S. society. Two similarly designed studies recently identified the economic and health impact of opioid abuse in patients with private or Medicaid insurance. The prevalence of opioid abuse was estimated to be over 10 times higher in Medicaid beneficiaries than private insurance populations, 87 versus 8 per 10,000, respectively. Opioid abusers incurred annual medical costs that were $14,054 to $6650 higher than nonabusers in patients with private insurance or Medicaid beneficiaries, respectively (P < .01 for both). Annual costs were similar for abusers with private insurance ($15,884) or Medicaid beneficiaries ($13,658). Costs for nonabuser Medicaid beneficiaries were $7008 versus $1830 for those with private insurance, which likely reflects the lower health status of the overall Medicaid population. In both studies, the prevalence of comorbidities associated with substance abuse or chronic pain were significantly higher in abusers than nonabusers. These studies confirm that opioid abuse is associated with comorbidities that increase direct medical costs for patients with private insurance and for Medicaid beneficiaries, increasing the societal burden of opioid abuse. SN - 1536-0539 UR - https://www.unboundmedicine.com/medline/citation/20718646/Cost_and_comorbidities_associated_with_opioid_abuse_in_managed_care_and_Medicaid_patients_in_the_United_Stated:_a_comparison_of_two_recently_published_studies_ L2 - https://www.tandfonline.com/doi/full/10.3109/15360288.2010.501851 DB - PRIME DP - Unbound Medicine ER -